Karyopharm Therapeutics (KPTI) Debt to Equity (2024 - 2025)
Karyopharm Therapeutics (KPTI) reported Debt to Equity of -$0.4 for Q4 2025, up 22.26% on a YoY basis from -$0.32 in Q4 2024, and down 10.43% quarter-over-quarter from -$0.36 in Q3 2025.
Karyopharm Therapeutics (KPTI) Debt to Equity (2024 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Debt to Equity for 2 years, with the latest figure at -$0.4 in Q4 2025.
- For the quarter ending Q4 2025, Debt to Equity rose 22.26% year-over-year to -$0.4; the trailing twelve-month figure through Dec 2025 stood at -$0.4 (up 22.26% YoY), and the FY2025 full-year result was -$0.4, up 22.26% from the prior year.
- Debt to Equity for Q4 2025 stood at -$0.4, down from -$0.36 in the prior quarter.
- The five-year high for Debt to Equity was -$0.36 in Q3 2025, with the low at -$0.71 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | -0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.40 |
| Sep 30, 2025 | -0.36 |
| Jun 30, 2025 | -0.40 |
| Mar 31, 2025 | -0.46 |
| Dec 31, 2024 | -0.51 |
| Sep 30, 2024 | -0.59 |
| Jun 30, 2024 | -0.71 |